Abacus FCF Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Abacus FCF Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7,565	Closed	-$1.38M	–	154
2021 Q2	$1.38M	Sell	7,565 -561	-7%	-$96.3K	0.71%	51
2021 Q1	$1.26M	Buy	+8,126	New	+$1.26M	0.64%	59
2020 Q3	–	Sell	-9,714	Closed	-$1.09M	–	95
2020 Q2	$1.09M	Buy	+9,714	New	+$1.03M	1.04%	55

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Abacus FCF Advisors's ALXN Position: Q3 2021 in Review

Abacus FCF Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 7,565 shares — an estimated $1.38M sold.

Abacus FCF Advisors first reported a position in ALXN in Q2 2020 and held it in 3 quarters. The position peaked at $1.38M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Abacus FCF Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Abacus FCF Advisors sold 7,565 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.38M.
Abacus FCF Advisors first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 3 quarters.
Abacus FCF Advisors's Alexion Pharmaceuticals position peaked at $1.38M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Abacus FCF Advisors's 13F filing for Q3 2021, filed 12 Oct 2021.